<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nina Van Goethem</style></author><author><style face="normal" font="default" size="100%">Pui Yan Jenny Chung</style></author><author><style face="normal" font="default" size="100%">Marjan Meurisse</style></author><author><style face="normal" font="default" size="100%">Mathil Vandromme</style></author><author><style face="normal" font="default" size="100%">Laurane De Mot</style></author><author><style face="normal" font="default" size="100%">Ruben Brondeel</style></author><author><style face="normal" font="default" size="100%">Veerle Stouten</style></author><author><style face="normal" font="default" size="100%">Sofieke Klamer</style></author><author><style face="normal" font="default" size="100%">Lize Cuypers</style></author><author><style face="normal" font="default" size="100%">Toon Braeye</style></author><author><style face="normal" font="default" size="100%">Lucy Catteau</style></author><author><style face="normal" font="default" size="100%">Louis Nevejan</style></author><author><style face="normal" font="default" size="100%">Joris Van Loenhout</style></author><author><style face="normal" font="default" size="100%">Koen Blot</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021-2022.</style></title><secondary-title><style face="normal" font="default" size="100%">Viruses</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ADOLESCENT</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Seasons</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jun 14</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;This retrospective multi-center matched cohort study assessed the risk for severe COVID-19 (combination of severity indicators), intensive care unit (ICU) admission, and in-hospital mortality in hospitalized patients when infected with the Omicron variant compared to when infected with the Delta variant. The study is based on a causal framework using individually-linked data from national COVID-19 registries. The study population consisted of 954 COVID-19 patients (of which, 445 were infected with Omicron) above 18 years old admitted to a Belgian hospital during the autumn and winter season 2021-2022, and with available viral genomic data. Patients were matched based on the hospital, whereas other possible confounders (demographics, comorbidities, vaccination status, socio-economic status, and ICU occupancy) were adjusted for by using a multivariable logistic regression analysis. The estimated standardized risk for severe COVID-19 and ICU admission in hospitalized patients was significantly lower (RR = 0.63; 95% CI (0.30; 0.97) and RR = 0.56; 95% CI (0.14; 0.99), respectively) when infected with the Omicron variant, whereas in-hospital mortality was not significantly different according to the SARS-CoV-2 variant (RR = 0.78, 95% CI (0.28-1.29)). This study demonstrates the added value of integrated genomic and clinical surveillance to recognize the multifactorial nature of COVID-19 pathogenesis.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue></record></records></xml>